Weight-loss drug Wegovy helps grow Danish GDP 

Growth in second quarter in particular driven by an 'exceptionally strong Danish pharmaceutical sector', analyst says

Wegovy weight-loss drug: Novo’s meteoric rise has pushed its market value above Denmark’s GDP.

Denmark’s economy expanded for the third consecutive quarter as Novo Nordisk, the maker of Wegovy weight-loss drug, and other Danish drug firms tap massive demand.

Gross domestic product grew 0.2% in the second quarter from the previous three months, as Denmark has outperformed most of its rich continental peers since the pandemic.